John F. Tomayko, MD, is Chief Medical Officer of Spero Therapeutics. Previously, he was a Senior Director of Clinical Development in the Infectious Diseases therapeutic unit at GlaxoSmithKline. During his fourteen year tenure at GlaxoSmithKline, Dr. Tomayko led the development of four antibacterial compounds and also an investigational therapy for severe sepsis. He has been actively involved in multiple industry interactions with FDA and other groups aiming to streamline the clinical development pathways for antibacterial agents addressing unmet need. He is a panelist on the Brookings Council of Antibacterial Drug Development, a member the Infectious Diseases Society of America, Society of Critical Care Medicine, and American Society of Microbiology. He is an author or co-author of over twenty seven abstracts and peer-reviewed articles in such journals as Critical Care Medicine, Antibacterial Agents and Chemotherapy, and Lancet Infectious Diseases.
Dr. Tomayko received his MD degree from the University of Pittsburgh, School of Medicine and completed a residency in Internal Medicine at Rush Presbyterian-St. Luke’s Medical Center in Chicago. He then completed his fellowship in Infectious Diseases at the University of Texas Health Sciences Center in Houston where he received a National Foundation of Infectious Diseases Fellowship award. He is board certified in internal medicine and infectious diseases. Following fellowship, he actively practiced infectious diseases and transplant medicine in Dallas, Texas.